首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   132347篇
  免费   9166篇
  国内免费   467篇
耳鼻咽喉   1714篇
儿科学   3560篇
妇产科学   2228篇
基础医学   17006篇
口腔科学   2526篇
临床医学   13437篇
内科学   27827篇
皮肤病学   2068篇
神经病学   12566篇
特种医学   4492篇
外国民族医学   4篇
外科学   19187篇
综合类   1978篇
现状与发展   1篇
一般理论   176篇
预防医学   12110篇
眼科学   3047篇
药学   9275篇
  2篇
中国医学   176篇
肿瘤学   8600篇
  2023年   619篇
  2022年   1027篇
  2021年   2494篇
  2020年   1460篇
  2019年   2367篇
  2018年   2733篇
  2017年   2072篇
  2016年   2247篇
  2015年   2714篇
  2014年   3858篇
  2013年   5809篇
  2012年   8473篇
  2011年   8946篇
  2010年   5044篇
  2009年   4754篇
  2008年   8406篇
  2007年   8850篇
  2006年   8681篇
  2005年   8938篇
  2004年   8478篇
  2003年   8219篇
  2002年   7813篇
  2001年   1268篇
  2000年   999篇
  1999年   1304篇
  1998年   1741篇
  1997年   1468篇
  1996年   1203篇
  1995年   1179篇
  1994年   977篇
  1993年   972篇
  1992年   788篇
  1991年   739篇
  1990年   721篇
  1989年   672篇
  1988年   611篇
  1987年   565篇
  1986年   564篇
  1985年   693篇
  1984年   850篇
  1983年   847篇
  1982年   1171篇
  1981年   1061篇
  1980年   961篇
  1979年   483篇
  1978年   602篇
  1977年   565篇
  1976年   472篇
  1975年   424篇
  1974年   382篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.

Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.

Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.  相似文献   

5.
6.
7.
8.

Background

Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.

Methods

Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.

Results

Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).

Conclusions

Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号